Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy

HIV Populations Are Large and Accumulate High Genetic Diversity in a Nonlinear Fashion

(2013) F. Maldarelli et al.   JOURNAL OF VIROLOGY

An Increasing Proportion of Monotypic HIV-1 DNA Sequences during Antiretroviral Treatment Suggests Proliferation of HIV-Infected Cells

(2012) Thor A. Wagner et al.   JOURNAL OF VIROLOGY

Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study

(2011) Josep M Llibre et al.   ANTIVIRAL THERAPY

A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response

(2011) Hiroyu Hatano et al.   JOURNAL OF INFECTIOUS DISEASES

MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods

(2011) K. Tamura et al.   MOLECULAR BIOLOGY AND EVOLUTION

Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy

(2010) D. McMahon et al.   CLINICAL INFECTIOUS DISEASES

Differences in HIV Burden and Immune Activation within the Gut of HIV‐Positive Patients Receiving Suppressive Antiretroviral Therapy

(2010) Steven A. Yukl et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 Continues To Replicate and Evolve in Patients with Natural Control of HIV Infection

(2010) H. Mens et al.   JOURNAL OF VIROLOGY

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

Multi-site adaptation in the presence of infrequent recombination

(2010) Igor M. Rouzine et al.   THEORETICAL POPULATION BIOLOGY

Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy

(2010) Binshan Shi et al.   VIROLOGY

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

(2010) Rajesh T. Gandhi et al.   PLOS MEDICINE

Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase

(2009) Mary Kearney et al.   AIDS

Identification of Ongoing Human Immunodeficiency Virus Type 1 (HIV-1) Replication in Residual Viremia during Recombinant HIV-1 Poxvirus Immunizations in Patients with Clinically Undetectable Viral Loads on Durable Suppressive Highly Active Antiretroviral Therapy

(2009) C. Shiu et al.   JOURNAL OF VIROLOGY

Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy

(2009) T. P. Brennan et al.   JOURNAL OF VIROLOGY

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

(2009) J. B. Dinoso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Persistence of HIV in Gut‐Associated Lymphoid Tissue despite Long‐Term Antiretroviral Therapy

(2008) Tae‐Wook Chun et al.   JOURNAL OF INFECTIOUS DISEASES

Human Immunodeficiency Virus Type 1 Population Genetics and Adaptation in Newly Infected Individuals

(2008) M. Kearney et al.   JOURNAL OF VIROLOGY

Immune epitope database analysis resource (IEDB-AR)

(2008) Q. Zhang et al.   NUCLEIC ACIDS RESEARCH

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

(2008) S. Palmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIV rebounds from latently infected cells, rather than from continuing low-level replication

(2008) B. Joos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA